In addition, low ENPP1 expression in pre-treatment biopsy samples obtained from breast cancer patients predicted their response to pembrolizumab (anti-PD-1) as a neoadjuvant therapy and distant-metastasis free survival (DMFS) up to 7 y. This evidence concerns the gene PDCD1 and breast cancer.